Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis
- 4 April 2021
- journal article
- research article
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 15 (6) , 1-8
Abstract
Purpose of Review Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening disease that disproportionately affects older adults and people of African descent. This review discusses current knowledge regarding racial and ethnic disparities in the diagnosis and management of ATTR-CM. Recent Findings Historically, ATTR-CM was thought to be a rare cause of heart failure. Recent evidence has shown that ATTR-CM is more common among older adults, men, and people of African descent. In addition, significant geographic variation exists in the identification of amyloid cardiomyopathy. Despite the high burden of ATTR-CM among Black individuals, most clinical data for ATTR-CM are from North America and Europe. Moreover, only a minority of clinical trial participants thus far have been Black patients. In addition to racial differences, socioeconomic disparities may be further compounded by the potentially prohibitive cost and limited accessibility of disease-modifying ATTR therapies. Summary ATTR-CM is an important cause of heart failure that disproportionately affects people of African descent. Efforts to promote earlier identification of ATTR-CM in general practice will likely improve clinical outcomes for all groups. Future trials should strive to enroll a higher proportion of Black patients. Furthermore, enhanced efforts are warranted to improve treatment accessibility among racial and ethnic minority groups that may be more likely to be affected by ATTR-CM.Keywords
Funding Information
- American Heart Association (19AMFDP34990036)
- National Institutes of Health (KL2TR003143)
This publication has 69 references indexed in Scilit:
- Safety and Efficacy of RNAi Therapy for Transthyretin AmyloidosisNew England Journal of Medicine, 2013
- Guideline of transthyretin-related hereditary amyloidosis for cliniciansOrphanet Journal of Rare Diseases, 2013
- Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS)American Heart Journal, 2012
- Progression of transthyretin amyloid neuropathy after liver transplantationNeurology, 2010
- African-American Women Have a Higher Risk for Developing Peripartum CardiomyopathyJACC, 2010
- Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish populationAmyloid, 2008
- Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99m Tc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid ScintigraphyJACC, 2005
- Haplotypes and DNA sequence variation within and surrounding the transthyretin gene: genotype–phenotype correlations in familial amyloid polyneuropathy (V30M) in Portugal and SwedenEuropean Journal of Human Genetics, 2003
- Racial Differences in the Outcome of Left Ventricular DysfunctionNew England Journal of Medicine, 1999
- Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP‐met30)Clinical Genetics, 1991